Do Clinical Outcomes and Quality of Life Differ by the Number of Antianginals for Stable Ischemic Heart Disease? Insights from the BARI 2D Trial

Medical therapy, including antianginal treatment, is the cornerstone in the management of stable ischemic heart disease (SIHD). However, it remains unclear whether combining antianginal agents provides benefits beyond monotherapy in terms of quality of life (QoL) and cardiovascular outcomes. We used data from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial, which compared cardiovascular and QoL outcomes in patients with SIHD and diabetes mellitus randomized to revascularization with intensive medical therapy or intensive medical therapy alone.

Source: The American Journal of Cardiology - January 15, 2024 Category: Cardiology Authors: Yasser Jamil, Dae Yong Park, Luis More Verde, Matthew W. Sherwood, Behnam N. Tehrani, Wayne B. Batchelor, Jennifer Frampton, Abdulla A. Damluji, Michael G. Nanna Source Type: research